Acinetobacter baumannii causes a wide range of severe infections among compromised and injured patients worldwide. The relevance of these infections are, in part, due to the ability of this pathogen to sense and react to environmental and host stress signals, allowing it to persist and disseminate in medical settings and the human host. This review summarizes current knowledge on the roles that environmental and cellular stressors play in the ability of A. baumannii to resist nutrient deprivation, oxidative and nitrosative injury, and even the presence of the commonly used antiseptic ethanol, which could serve as a nutrient- and virulence-enhancing signal rather than just being a convenient disinfectant. Emerging experimental evidence supports the role of some of these responses in the pathogenesis of the infections A. baumannii causes in humans and its capacity to resist antibiotics and host response effectors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638152 | PMC |
| http://dx.doi.org/10.2217/fmb.12.150 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidemiology, Clinical Characteristics and Treatment Outcomes of Infection at a Regional Hospital in Thailand.
Infect Drug Resist
January 2025
Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Objective: This retrospective cohort study evaluated the treatment outcome of infection.
Methods: In this retrospective cohort study, 476 patients with () infection who were admitted to the internal medicine ward at Lampang Hospital, Lampang, Thailand, from 1 January 2020 to 31 December 2020 were enrolled. Medical records were reviewed.
The Clinical Impression of NDM-producing in Intensive Care Units of the University Referral Hospital in North India.
Indian J Crit Care Med
November 2024
Department of Critical Care Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India.
Aims And Background: Carbapenem-resistant (CRAb), a major public health threat, causes severe infections in Intensive Care Unit (ICU) patients. It resists β-lactam antibiotics through mechanisms like New Delhi metallo-beta-lactamase (NDM).
Materials And Methods: In ICU patients, 69 species were isolated from 86 non-fermenting Gram-negative bacilli.
Authors' reply: "Effect of colistin combined with sulbactam: 9 g versus 12 g per day on mortality in the treatment of carbapenems resistant Acinetobacter baumannii pneumonia: a randomized controlled trial".
Int J Infect Dis
January 2025
Division of Infectious Disease, Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand.
In-vitro susceptibility of cefiderocol and other comparators in carbapenem-resistant gram-negative bacilli: A study from India.
Indian J Med Microbiol
January 2025
Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India.
Introduction: Cefiderocol is a parenteral catechol-type siderophore cephalosporin, which has been approved for the treatment of gram-negative bacterial infections. Its activity among the carbapenem-resistant gram negative bacilli (CR-GNBs) in India is largely unknown.
Methodology: We tested in-vitro susceptibility of cefiderocol in 84 CR-GNB [ carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA) , carbapenem-resistant Escherichia coli (CREC) and carbapenem-resistant Klebsiella pneumoniae (CRKP)] by broth microdilution(BMD) and disc diffusion (DD) using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints and concordance of DD was compared with BMD.
Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK/PD.
Antimicrob Agents Chemother
January 2025
Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
Eravacycline is a broad-spectrum fluorocycline currently approved for complicated intra-abdominal infections (cIAIs). In lung-infection models, it is effective against methicillin-resistant (MRSA) and tetracycline-resistant MRSA. As such, we aimed to develop a population pharmacokinetic/pharmacodynamic (PK/PD) model to evaluate eravacycline's pulmonary distribution and kinetics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!